Roche has unveiled a strategic plan to become a leading obesity company by 2030 without relying on a single blockbuster drug. The plan leverages multiple pipeline assets, including the dual GLP-1/GIP receptor agonist CT-388 entering phase 3 and the amylin analog petrelintide, acquired via recent deals. Roche emphasizes its manufacturing capabilities, commercial footprint in over 150 countries, and pharma-diagnostics integration as core strengths to capture significant market share in obesity therapeutics.